Canaccord Genuity set a $11.00 price objective on Lipocine Inc. (NASDAQ:LPCN) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the company. Roth Capital set a $38.00 target price on Lipocine and gave the stock a buy rating in a report on Tuesday, June 20th. HC Wainwright reiterated a buy rating and issued a $25.00 target price on shares of Lipocine in a report on Wednesday, April 26th.

Shares of Lipocine (LPCN) traded up 1.34% during mid-day trading on Monday, reaching $4.55. The company’s stock had a trading volume of 59,114 shares. The company’s 50-day moving average price is $4.36 and its 200-day moving average price is $3.96. The stock’s market capitalization is $87.64 million. Lipocine has a 12-month low of $3.03 and a 12-month high of $5.90.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.01. On average, equities research analysts forecast that Lipocine will post ($1.12) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Lipocine Inc. (NASDAQ:LPCN) Given a $11.00 Price Target at Canaccord Genuity” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/08/lipocine-inc-nasdaqlpcn-given-a-11-00-price-target-at-canaccord-genuity.html.

Institutional investors have recently made changes to their positions in the company. Federated Investors Inc. PA boosted its position in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 7,429 shares during the period. LMR Partners LLP bought a new position in shares of Lipocine during the second quarter worth approximately $173,000. KCG Holdings Inc. boosted its position in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 7,219 shares during the period. Parametric Portfolio Associates LLC boosted its position in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock worth $229,000 after buying an additional 12,518 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Lipocine by 99.4% in the first quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock worth $513,000 after buying an additional 65,600 shares during the period. Hedge funds and other institutional investors own 38.88% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.